IL2 and primary cutaneous T-cell non-Hodgkin lymphoma: The approval of DT-IL2 (DAB389-IL2) was granted for the treatment of cutaneous T-cell lymphoma and DT-IL3 (DAB389-IL3) for the treatment of blastic plasmacytoid dendritic cell neoplasm.